Trubogli- DS
New Armamentarium for PPHG Management


Composition : Voglibose 0.3mg + Repaglinide 1mg

Form : Tablets / Pack : 1 x 10 / Type : A A

Description : A non-randomized, open labeled, non-comparative, single-centric study was conducted in total of 20 type 2 diabetes mellitus (T2DM) patients (9 men and 11 women, mean age 69.07 ± 3.495 years). Each patient was administered a fixed dose combination of voglibose 0.3mg & repaglinide 0.5/1mg three times a day, just before each meal for 30 days. Fasting blood glucose (FBG) & postprandial blood glucose (PPBG) was performed at baseline & at the end of study as assessment tools. At the end of study data was extractable only in 15 patients because 5 patient dropped out as they did not turn up for follow up at day 30.Postprandial blood glucose reduced significantly {-61.67mg/dl (95% confidence interval -76.79 to -46.54 p<0.0001)} from baseline at day 30. Also a significant reduction (p<0.0001) was found with FBG {-42.13mg/dl (Confidence interval -61.25 to -23.02 P value <0.0001)} at end of day 30. There were no adverse events reported including hypoglycemia. Voglibose and Repaglinide combination was effective and safe for the management of PPHG in T2DM patients- Global Journal of Obesity, Diabetes and Metabolic Syndrome- 2017

View more products with following salts

Trubogli- XL
New Armamentarium for PPHG Management


Composition : Voglibose 0.3mg + Repaglinide 0.5mg

Form : Tablets / Pack : 1 x 10"s / Type : A A

Description : A non-randomized, open labeled, non-comparative, single-centric study was conducted in total of 20 type 2 diabetes mellitus (T2DM) patients (9 men and 11 women, mean age 69.07 ± 3.495 years). Each patient was administered a fixed dose combination of voglibose 0.3mg & repaglinide 0.5/1mg three times a day, just before each meal for 30 days. Fasting blood glucose (FBG) & postprandial blood glucose (PPBG) was performed at baseline & at the end of study as assessment tools. At the end of study data was extractable only in 15 patients because 5 patient dropped out as they did not turn up for follow up at day 30.Postprandial blood glucose reduced significantly {-61.67mg/dl (95% confidence interval -76.79 to -46.54 p<0.0001)} from baseline at day 30. Also a significant reduction (p<0.0001) was found with FBG {-42.13mg/dl (Confidence interval -61.25 to -23.02 P value <0.0001)} at end of day 30. There were no adverse events reported including hypoglycemia. Voglibose and Repaglinide combination was effective and safe for the management of PPHG in T2DM patients- Global Journal of Obesity, Diabetes and Metabolic Syndrome- 2017

View more products with following salts

Trubogli Plus
New Armamentarium for PPHG Management


Composition : Voglibose 0.2mg + Repaglinide 0.5mg

Form : Tablets / Pack : 1 x 10"s / Type : A A

Description : A non-randomized, open labeled, non-comparative, single-centric study was conducted in total of 20 type 2 diabetes mellitus (T2DM) patients (9 men and 11 women, mean age 69.07 ± 3.495 years). Each patient was administered a fixed dose combination of voglibose 0.3mg & repaglinide 0.5/1mg three times a day, just before each meal for 30 days. Fasting blood glucose (FBG) & postprandial blood glucose (PPBG) was performed at baseline & at the end of study as assessment tools. At the end of study data was extractable only in 15 patients because 5 patient dropped out as they did not turn up for follow up at day 30.Postprandial blood glucose reduced significantly {-61.67mg/dl (95% confidence interval -76.79 to -46.54 p<0.0001)} from baseline at day 30. Also a significant reduction (p<0.0001) was found with FBG {-42.13mg/dl (Confidence interval -61.25 to -23.02 P value <0.0001)} at end of day 30. There were no adverse events reported including hypoglycemia. Voglibose and Repaglinide combination was effective and safe for the management of PPHG in T2DM patients- Global Journal of Obesity, Diabetes and Metabolic Syndrome- 2017

View more products with following salts

Trubogli Forte
New Armamentarium for PPHG Management


Composition : Voglibose 0.2mg + Repaglinide 1mg

Form : Tablets / Pack : 1 x 10"s / Type : A A

Description : A non-randomized, open labeled, non-comparative, single-centric study was conducted in total of 20 type 2 diabetes mellitus (T2DM) patients (9 men and 11 women, mean age 69.07 ± 3.495 years). Each patient was administered a fixed dose combination of voglibose 0.3mg & repaglinide 0.5/1mg three times a day, just before each meal for 30 days. Fasting blood glucose (FBG) & postprandial blood glucose (PPBG) was performed at baseline & at the end of study as assessment tools. At the end of study data was extractable only in 15 patients because 5 patient dropped out as they did not turn up for follow up at day 30.Postprandial blood glucose reduced significantly {-61.67mg/dl (95% confidence interval -76.79 to -46.54 p<0.0001)} from baseline at day 30. Also a significant reduction (p<0.0001) was found with FBG {-42.13mg/dl (Confidence interval -61.25 to -23.02 P value <0.0001)} at end of day 30. There were no adverse events reported including hypoglycemia. Voglibose and Repaglinide combination was effective and safe for the management of PPHG in T2DM patients- Global Journal of Obesity, Diabetes and Metabolic Syndrome- 2017

View more products with following salts

Grilp – 10
An Adjunct To Diet And Exercise


Composition : Dapagliflozin 10mg

Form : Tablets / Pack : 1 X 10's / Type : AA

Description : Dapagliflozin is in a class of drug called SGLT2 inhibitors that works by targeting and helping to stop sodium-glucose transport proteins from allowing glucose that has been filtered out of the blood by the kidneys to be reabsorbed back into the blood. The SGLT2 proteins are responsible for 90% of the glucose that is reabsorbed into the blood. By inhibiting the SGLT2 proteins. Dapagliflozin allows a significant amount of glucose in the blood to be removed by the kidneys and excreted in the urine. SGLT2i have moderate benefits on atherosclerotic major adverse cardiovascular events that seem confined to patients with established atherosclerotic cardiovascular disease. However, they have robust benefits on reducing hospitalisation for heart failure and progression of renal disease regardless of existing atherosclerotic cardiovascular disease or a history of heart failure - The Lancet, Vol.- 393, Iss.-10166, p31-39.

View more products with following salts